Mechanism of action
Lorazepam is a benzodiazepine that acts as a positive allosteric modulator of the gamma-aminobutyric acid A (GABA-A) receptor. It binds to a specific site on the GABA-A receptor complex, distinct from the GABA binding site, and enhances the receptor's affinity for GABA.
When GABA binds to the GABA-A receptor in the presence of lorazepam, the frequency of chloride channel opening increases, leading to hyperpolarization of the neuronal membrane. This hyperpolarization reduces neuronal excitability throughout the central nervous system, producing anxiolytic, sedative, anticonvulsant, and muscle relaxant effects.
Key pharmacologic distinction: Unlike many benzodiazepines (such as diazepam and midazolam), lorazepam undergoes direct conjugation with glucuronic acid (phase II metabolism) rather than oxidative metabolism via the cytochrome P450 system. This metabolic pathway produces inactive glucuronide metabolites that are renally excreted. This characteristic makes lorazepam particularly useful in patients with hepatic impairment and reduces the potential for drug-drug interactions compared to oxidatively metabolized benzodiazepines.
- Lorazepam undergoes glucuronidation only (no CYP450 metabolism), making it safer in liver disease and reducing drug interactions
- First-line benzodiazepine for status epilepticus with longer anticonvulsant duration than diazepam (12-24 hours vs 15-30 minutes)
- Reliably absorbed intramuscularly, unlike diazepam which has erratic IM absorption
- Black box warning: concomitant use with opioids increases risk of profound sedation, respiratory depression, and death
- Paradoxical disinhibition occurs more frequently in elderly and pediatric patients (agitation instead of sedation)
- IV formulation contains propylene glycol; prolonged high-dose infusions can cause lactic acidosis and acute kidney injury
- Abrupt discontinuation after chronic use can precipitate withdrawal seizures; always taper gradually
- Category D in pregnancy; associated with cleft lip/palate in first trimester and neonatal withdrawal syndrome
Indications
Lorazepam is approved and commonly used for:
- Anxiety disorders: Short-term management of severe anxiety or anxiety associated with depression
- Status epilepticus: First-line benzodiazepine for terminating seizures (intravenous or intramuscular administration)
- Insomnia: Short-term treatment of insomnia related to anxiety
- Preoperative sedation: Anxiolysis and amnesia before surgical procedures
- Alcohol withdrawal syndrome: Management of acute alcohol withdrawal symptoms
- Chemotherapy-induced nausea: Adjunctive treatment for anticipatory nausea and vomiting
- Agitation: Acute management of severe agitation in emergency settings
- Catatonia: Diagnostic and therapeutic trial in catatonic states
Lorazepam is particularly favored in hospital settings for its reliable intramuscular absorption, intermediate duration of action (6-8 hours), and lack of active metabolites.
Pharmacokinetics
Absorption: Well absorbed after oral administration with bioavailability of approximately 90%. Peak plasma concentrations occur within 2 hours of oral dosing. Intramuscular administration produces reliable absorption, unlike some other benzodiazepines.
Distribution: Lorazepam is approximately 85% protein-bound. Volume of distribution is 1.3 L/kg. It crosses the blood-brain barrier readily and is distributed into breast milk.
Metabolism: Lorazepam undergoes direct glucuronidation to lorazepam glucuronide, an inactive metabolite. This phase II conjugation reaction does not involve the cytochrome P450 system, which distinguishes lorazepam from oxidatively metabolized benzodiazepines like diazepam and alprazolam. This metabolic pathway is preserved even in significant hepatic dysfunction.
Elimination: The elimination half-life is approximately 12-18 hours in healthy adults, though this may be prolonged in elderly patients and those with renal impairment. Metabolites are excreted primarily in urine.
Special populations: Elderly patients experience increased sensitivity and prolonged half-life. Hepatic disease does not significantly affect clearance, but severe renal impairment may lead to accumulation of glucuronide metabolites.
Adverse effects
Common adverse effects
- Central nervous system: Sedation, drowsiness, dizziness, ataxia, confusion, cognitive impairment, anterograde amnesia
- Psychiatric: Paradoxical reactions (agitation, irritability, disinhibition) particularly in elderly and pediatric patients
- Neuromuscular: Muscle weakness, fatigue
- Gastrointestinal: Nausea, constipation
Serious adverse effects
- Respiratory depression: Risk increases with high doses, rapid intravenous administration, or concurrent use of opioids or other CNS depressants. Can be life-threatening.
- Dependence and withdrawal: Physical and psychological dependence develops with prolonged use (typically beyond 2-4 weeks). Abrupt discontinuation can precipitate withdrawal syndrome including seizures, tremor, anxiety, insomnia, and rarely delirium.
- Cognitive impairment: Chronic use is associated with memory impairment, particularly in elderly patients
- Falls and fractures: Increased risk in elderly due to sedation, ataxia, and impaired coordination
- Propylene glycol toxicity: The intravenous formulation contains propylene glycol, which can cause lactic acidosis, hyperosmolality, and acute kidney injury with prolonged high-dose infusions
Black box warning
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients with inadequate alternative treatment options.
Contraindications and warnings
Absolute contraindications
- Hypersensitivity to lorazepam, other benzodiazepines, or formulation components
- Acute narrow-angle glaucoma
- Severe respiratory insufficiency (relative contraindication for oral; absolute for intravenous)
- Sleep apnea syndrome (severe)
- Myasthenia gravis
Warnings and precautions
Respiratory compromise: Use with extreme caution in patients with chronic obstructive pulmonary disease, sleep apnea, or other conditions affecting respiratory function. Intravenous administration requires availability of resuscitative equipment and flumazenil.
Elderly patients: Increased sensitivity to CNS effects, higher risk of falls, cognitive impairment, and paradoxical reactions. Consider reduced doses.
Pregnancy: Category D. Benzodiazepines cross the placenta and are associated with increased risk of congenital malformations (particularly cleft lip/palate) when used in the first trimester. Neonatal withdrawal syndrome and floppy infant syndrome can occur with use near delivery.
Lactation: Lorazepam is excreted in breast milk. Sedation, poor feeding, and withdrawal have been reported in breastfed infants.
Substance abuse history: Use with caution; benzodiazepines have abuse potential and should be prescribed judiciously in patients with history of substance use disorders.
Hepatic impairment: Although lorazepam's glucuronidation pathway is relatively preserved in liver disease, increased sensitivity and prolonged effects may occur in severe hepatic dysfunction.
Renal impairment: Glucuronide metabolites may accumulate; monitor for excessive sedation.
Drug interactions
Pharmacodynamic interactions
CNS depressants: Additive sedation and respiratory depression occur with:
- Opioid analgesics (black box warning for combined use)
- Alcohol
- Other benzodiazepines
- Barbiturates
- Sedating antihistamines
- Antipsychotics
- General anesthetics
Valproic acid: May displace lorazepam from protein binding sites, increasing free drug concentration and enhancing effects.
Probenecid: Inhibits glucuronidation, potentially increasing lorazepam levels and prolonging half-life.
Pharmacokinetic interactions
Lorazepam has minimal pharmacokinetic interactions because it does not undergo cytochrome P450 metabolism. Unlike diazepam and alprazolam, lorazepam levels are not significantly affected by CYP3A4 inhibitors (such as azole antifungals, macrolides, or protease inhibitors) or inducers (such as rifampin, carbamazepine, or phenytoin).
This favorable interaction profile makes lorazepam particularly useful in medically complex patients receiving multiple medications.
Effects on other drugs
Lorazepam does not significantly inhibit or induce drug-metabolizing enzymes and generally does not affect the pharmacokinetics of other medications.
Clinical pearls
LOL (Lorazepam, Oxazepam, Lorazepam): These benzodiazepines undergo glucuronidation only, making them preferred in hepatic disease and reducing drug interaction concerns.
Status epilepticus management: Lorazepam 0.1 mg/kg IV is a first-line agent with longer duration of anticonvulsant effect (12-24 hours) compared to diazepam (15-30 minutes), reducing seizure recurrence risk.
IM absorption: Unlike diazepam, lorazepam is reliably absorbed intramuscularly, making it useful when IV access is unavailable.
Perioperative use: Lorazepam produces reliable anxiolysis and anterograde amnesia, which is desirable preoperatively but may complicate postoperative cognitive assessment.
Alcohol withdrawal: Lorazepam is commonly used in CIWA protocols. Its intermediate half-life provides smooth coverage without excessive accumulation.
Propylene glycol toxicity: High-dose continuous IV infusions (such as for ICU sedation or refractory status epilepticus) can cause propylene glycol accumulation. Monitor for metabolic acidosis, elevated osmolar gap, and acute kidney injury.
Tapering: Always taper gradually when discontinuing after prolonged use. A 10-25% dose reduction every 1-2 weeks is a typical strategy to minimize withdrawal symptoms.
Paradoxical disinhibition: Children and elderly patients may experience agitation, aggression, or disinhibition rather than sedation—consider discontinuation if this occurs.
Flumazenil: The benzodiazepine antagonist can reverse lorazepam's effects but may precipitate withdrawal seizures in dependent patients.
Comparison to other benzodiazepines: Lorazepam has intermediate onset (slower than midazolam, faster than clonazepam) and intermediate duration (longer than midazolam, shorter than diazepam's active metabolites).
LOL for hepatic safety: Lorazepam, Oxazepam, and Temazepam undergo glucuronidation (LOT = glucuronidation only)
Practice questions
1. A 68-year-old man with cirrhosis secondary to chronic hepatitis C presents to the emergency department with alcohol withdrawal symptoms including tremor, tachycardia, and anxiety. His liver function tests show elevated transaminases and bilirubin. Which benzodiazepine is most appropriate for managing his withdrawal symptoms?
2. A 32-year-old woman is brought to the emergency department with ongoing generalized tonic-clonic seizures that started 20 minutes ago. IV access is established. Which medication provides the longest duration of seizure control after initial administration?
3. A 55-year-old man on a continuous lorazepam infusion for sedation in the ICU for 5 days develops an anion gap metabolic acidosis with elevated lactate, acute kidney injury, and an increased serum osmolar gap. Sepsis workup is negative. What is the most likely cause?
Frequently asked questions
How does lorazepam work?
Lorazepam enhances the activity of GABA, the brain's primary inhibitory neurotransmitter, by binding to GABA-A receptors and increasing chloride channel opening frequency. This causes neuronal hyperpolarization, reducing brain excitability and producing calming, sedative, and anticonvulsant effects. Unlike many other benzodiazepines, lorazepam is metabolized by direct glucuronidation rather than through the liver's cytochrome P450 enzyme system, making it safer in patients with liver disease.
What are the side effects of lorazepam?
Common side effects include drowsiness, dizziness, weakness, unsteadiness, and memory problems (especially difficulty forming new memories). Serious side effects include respiratory depression (especially when combined with opioids or alcohol), physical dependence with prolonged use, and withdrawal seizures if stopped abruptly. Elderly patients face increased risk of falls, confusion, and paradoxical agitation. The IV formulation can cause propylene glycol toxicity with prolonged high-dose use, leading to kidney injury and metabolic acidosis.
Is lorazepam a controlled substance?
Yes, lorazepam is a Schedule IV controlled substance in the United States under the Controlled Substances Act. This classification reflects its recognized medical use but also its potential for abuse, dependence, and diversion. Physical and psychological dependence can develop with regular use, typically within 2-4 weeks. Prescribers must follow controlled substance prescribing regulations, and patients should be counseled about the risks of dependence and the importance of not sharing medication.
Lorazepam vs diazepam — what is the difference?
The key differences are metabolism and duration. Lorazepam undergoes glucuronidation only (safer in liver disease, fewer drug interactions), while diazepam is metabolized by CYP450 enzymes to active metabolites, giving it a much longer effective duration. Lorazepam has reliable IM absorption; diazepam's IM absorption is erratic. For status epilepticus, lorazepam provides longer seizure control (12-24 hours vs 15-30 minutes for diazepam alone). Lorazepam has an intermediate half-life of 12-18 hours, whereas diazepam with its active metabolites can have effects lasting days.
Can you take lorazepam every day?
While lorazepam can be prescribed for daily use, it is generally recommended for short-term treatment (typically 2-4 weeks) due to risks of tolerance, dependence, and cognitive impairment with chronic use. Long-term daily use often leads to physical dependence, requiring gradual tapering to discontinue safely and avoid withdrawal seizures. For chronic anxiety, non-benzodiazepine options like SSRIs are preferred for long-term management. If daily lorazepam is necessary long-term, it should be at the lowest effective dose with regular reassessment by a physician.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N05BA06
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.